Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
GNVC's Cash-to-Debt is ranked higher than
99% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. GNVC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GNVC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.83  Med: 20.85 Max: No Debt
Current: No Debt
Equity-to-Asset 0.12
GNVC's Equity-to-Asset is ranked lower than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GNVC: 0.12 )
Ranked among companies with meaningful Equity-to-Asset only.
GNVC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.74 Max: 0.89
Current: 0.12
0.12
0.89
Piotroski F-Score: 2
Altman Z-Score: -86.58
Beneish M-Score: -5.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2585.97
GNVC's Operating Margin % is ranked lower than
84% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. GNVC: -2585.97 )
Ranked among companies with meaningful Operating Margin % only.
GNVC' s Operating Margin % Range Over the Past 10 Years
Min: -2585.97  Med: -151.31 Max: -42
Current: -2585.97
-2585.97
-42
Net Margin % -2447.76
GNVC's Net Margin % is ranked lower than
85% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. GNVC: -2447.76 )
Ranked among companies with meaningful Net Margin % only.
GNVC' s Net Margin % Range Over the Past 10 Years
Min: -2447.76  Med: -141.73 Max: -41.63
Current: -2447.76
-2447.76
-41.63
ROE % -167.71
GNVC's ROE % is ranked lower than
87% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. GNVC: -167.71 )
Ranked among companies with meaningful ROE % only.
GNVC' s ROE % Range Over the Past 10 Years
Min: -177.18  Med: -73.15 Max: -25.24
Current: -167.71
-177.18
-25.24
ROA % -102.36
GNVC's ROA % is ranked lower than
85% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. GNVC: -102.36 )
Ranked among companies with meaningful ROA % only.
GNVC' s ROA % Range Over the Past 10 Years
Min: -102.36  Med: -56.85 Max: -21.39
Current: -102.36
-102.36
-21.39
ROC (Joel Greenblatt) % -3010.34
GNVC's ROC (Joel Greenblatt) % is ranked lower than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. GNVC: -3010.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNVC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3010.34  Med: -1585.27 Max: -642.28
Current: -3010.34
-3010.34
-642.28
3-Year Revenue Growth Rate -55.80
GNVC's 3-Year Revenue Growth Rate is ranked lower than
85% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GNVC: -55.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GNVC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.8  Med: -21.6 Max: 6
Current: -55.8
-66.8
6
3-Year EBITDA Growth Rate -30.50
GNVC's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. GNVC: -30.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GNVC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -43.5  Med: -28.9 Max: 12.1
Current: -30.5
-43.5
12.1
3-Year EPS without NRI Growth Rate -28.80
GNVC's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. GNVC: -28.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GNVC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: -27.1 Max: 8.9
Current: -28.8
-42.8
8.9
GuruFocus has detected 5 Warning Signs with Genvec Inc GNVC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNVC's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GNVC Guru Trades in Q3 2016

Jim Simons 184,500 sh (+17.89%)
» More
Q4 2016

GNVC Guru Trades in Q4 2016

Jim Simons 27,760 sh (+50.46%)
» More
Q1 2017

GNVC Guru Trades in Q1 2017

Jim Simons 10,260 sh (-63.04%)
» More
Q2 2017

GNVC Guru Trades in Q2 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNVC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ASX:IMC, AMEX:BPMX, ASX:SUD, XTAE:CLPT, LSE:SNG, AMEX:CVM, XSAT:EUCI, NAS:DARE, BOM:512299, LSE:SBTX, NAS:NEOT, XTER:CUR, ASX:POH, MIC:ISKJ, NGM:MCNH MTF, NAS:JAGX, ROCO:4154, WAR:BML, ROCO:4732, LSE:COS » details
Traded in other countries:GVC2.Germany,
Headquarter Location:USA
Genvec Inc is a biopharmaceutical company. The Company is engaged in leveraging its proprietary AdenoVerse gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines.

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.

Ratios

vs
industry
vs
history
PB Ratio 27.98
GNVC's PB Ratio is ranked lower than
94% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. GNVC: 27.98 )
Ranked among companies with meaningful PB Ratio only.
GNVC' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.1 Max: 41.5
Current: 27.98
0.42
41.5
PS Ratio 48.26
GNVC's PS Ratio is ranked lower than
76% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. GNVC: 48.26 )
Ranked among companies with meaningful PS Ratio only.
GNVC' s PS Ratio Range Over the Past 10 Years
Min: 0.62  Med: 6.77 Max: 48.26
Current: 48.26
0.62
48.26
EV-to-EBIT -1.73
GNVC's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. GNVC: -1.73 )
Ranked among companies with meaningful EV-to-EBIT only.
GNVC' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.2  Med: -2.2 Max: 0.5
Current: -1.73
-24.2
0.5
EV-to-EBITDA -1.75
GNVC's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. GNVC: -1.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNVC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.7  Med: -2.3 Max: 0.5
Current: -1.75
-25.7
0.5
EV-to-Revenue 36.01
GNVC's EV-to-Revenue is ranked lower than
68% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. GNVC: 36.01 )
Ranked among companies with meaningful EV-to-Revenue only.
GNVC' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.7  Med: 4.2 Max: 36
Current: 36.01
-2.7
36
Current Ratio 2.09
GNVC's Current Ratio is ranked lower than
73% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GNVC: 2.09 )
Ranked among companies with meaningful Current Ratio only.
GNVC' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 4.39 Max: 8.55
Current: 2.09
1.46
8.55
Quick Ratio 2.09
GNVC's Quick Ratio is ranked lower than
69% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. GNVC: 2.09 )
Ranked among companies with meaningful Quick Ratio only.
GNVC' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 4.39 Max: 8.55
Current: 2.09
1.46
8.55
Days Sales Outstanding 91.52
GNVC's Days Sales Outstanding is ranked lower than
68% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. GNVC: 91.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNVC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.71  Med: 41.81 Max: 91.52
Current: 91.52
15.71
91.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.30
GNVC's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. GNVC: -18.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNVC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -139.6  Med: -13.2 Max: -2
Current: -18.3
-139.6
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 59.92
GNVC's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. GNVC: 59.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GNVC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.67  Med: 4.84 Max: 59.92
Current: 59.92
0.67
59.92
Price-to-Tangible-Book 27.65
GNVC's Price-to-Tangible-Book is ranked lower than
92% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. GNVC: 27.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GNVC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.58  Med: 3.4 Max: 27.98
Current: 27.65
0.58
27.98
Price-to-Median-PS-Value 7.12
GNVC's Price-to-Median-PS-Value is ranked lower than
97% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GNVC: 7.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNVC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.92 Max: 7.12
Current: 7.12
0.13
7.12
Earnings Yield (Greenblatt) % -57.80
GNVC's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. GNVC: -57.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNVC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26664.7  Med: -39.2 Max: 25748.8
Current: -57.8
-26664.7
25748.8

More Statistics

Revenue (TTM) (Mil) $0.34
EPS (TTM) $ -3.66
Short Percentage of Float14.25%
52-Week Range $2.70 - 10.44
Shares Outstanding (Mil)2.27

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 0 1 2
EPS ($) -2.81 -2.70 -3.00
EPS without NRI ($) -2.81 -2.70 -3.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}